April 5, 2005
Tigecycline data reveals MRSA efficacyTopics: Clinical Pharmacology
Methicillin resistant Staphylococcus aureus (MRSA) has become a prevalent nosocomial pathogen worldwide. The US Centers for Disease Control and Prevention estimate that between 60,000 and 80,000 Americans die each year from nosocomial infections and the cause in the majority of cases is S. aureus. A recent retrospective review of patients who underwent major surgery for head and neck cancer over a one year period showed that 25/55 (45 percent) of the patients became MRSA positive in the post-operative period studied.
But we are now hearing some good news on the MRSA front. Data from the first drug in a new class of antibiotics was presented at this year’s European Congress of Clinical Microbiology and Infectious Diseases(ECCMID) conference. The data provided evidence that Tigecycline, a semi-synthetic glycylcycline derived from the minocycline molecule, demonstrated its efficacy against a wide variety of gram-positive and gram-negative bacteria including multi-drug-resistant bugs. Tigecycline has documented activity against tetracycline-resistant gram-positive and gram-negative pathogens refractory by both efflux and ribosomal protection mechanisms.
Experts warn that ‘the world may be running out of effective antibiotics, and statistics from pharmaceutical companies reveal that few new antibiotics have been developed in the last 20 years and very few are currently in the pipeline for development.
Cross posted at Hyscience
Posted by Richard at April 5, 2005 1:06 PM
Articles Related to Clinical Pharmacology: